1. Home
  2. ALT vs ABVX Comparison

ALT vs ABVX Comparison

Compare ALT & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALT
  • ABVX
  • Stock Information
  • Founded
  • ALT 1997
  • ABVX 2013
  • Country
  • ALT United States
  • ABVX France
  • Employees
  • ALT N/A
  • ABVX N/A
  • Industry
  • ALT Biotechnology: Pharmaceutical Preparations
  • ABVX
  • Sector
  • ALT Health Care
  • ABVX
  • Exchange
  • ALT Nasdaq
  • ABVX Nasdaq
  • Market Cap
  • ALT 472.3M
  • ABVX 451.5M
  • IPO Year
  • ALT N/A
  • ABVX N/A
  • Fundamental
  • Price
  • ALT $5.59
  • ABVX $6.71
  • Analyst Decision
  • ALT Strong Buy
  • ABVX Strong Buy
  • Analyst Count
  • ALT 7
  • ABVX 5
  • Target Price
  • ALT $21.00
  • ABVX $33.80
  • AVG Volume (30 Days)
  • ALT 2.0M
  • ABVX 96.0K
  • Earning Date
  • ALT 05-13-2025
  • ABVX 03-24-2025
  • Dividend Yield
  • ALT N/A
  • ABVX N/A
  • EPS Growth
  • ALT N/A
  • ABVX N/A
  • EPS
  • ALT N/A
  • ABVX N/A
  • Revenue
  • ALT $20,000.00
  • ABVX $11,172,999.00
  • Revenue This Year
  • ALT N/A
  • ABVX $284.20
  • Revenue Next Year
  • ALT N/A
  • ABVX N/A
  • P/E Ratio
  • ALT N/A
  • ABVX N/A
  • Revenue Growth
  • ALT N/A
  • ABVX 135.94
  • 52 Week Low
  • ALT $3.55
  • ABVX $4.77
  • 52 Week High
  • ALT $11.16
  • ABVX $14.75
  • Technical
  • Relative Strength Index (RSI)
  • ALT 56.67
  • ABVX 50.68
  • Support Level
  • ALT $4.95
  • ABVX $6.54
  • Resistance Level
  • ALT $6.05
  • ABVX $7.83
  • Average True Range (ATR)
  • ALT 0.37
  • ABVX 0.54
  • MACD
  • ALT 0.10
  • ABVX -0.00
  • Stochastic Oscillator
  • ALT 65.67
  • ABVX 30.00

About ALT Altimmune Inc.

Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.

About ABVX Abivax SA American

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.

Share on Social Networks: